Chiesi Farmaceutici S.p.a.

Andrea Rizzi

Fabio Rancati

Ian Linney

Gabriele Amari

Chris Knight

Laura Carzaniga

Gino Villetti

Elisabetta Armani

Wesley Peter Blackaby

Carmelida Capaldi

Ilaria Peretto

Luca Raveglia

Wolfgang Schmidt

Bruno Pietro Imbimbo

Stefano Radaelli

Eleonora Ghidini

Charles Baker-Glenn

Mauro Riccaboni

Ben Whittaker

Juan Lorenzo Catena Ruiz

Matteo Biagetti

Isabel Masip Masip

Mafalda Pagano

Michael Barnes

Elena La Porta

Andrea Virdis

Herve Van De Poel

Claudia Beato

Herve′ Van De Poel

Anna Rencurosi

Riccardo Patacchini

Valentina Cenacchi

Charles Baker-glenn

Anna Karawajczyk

David Edward Clark

Hervé Van De Poël

Barbara Karolina Wolek

Keith Christopher Knight

Ben Paul Whittaker

Nicolò Iotti

Stefano Levanto

Wesley Blackaby

Toby Matthew Grover Mullins

Robert Andrew Heald

Jonathan Mark Sutton

Hervé Van De PÖEL

The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

Amido cyclohexane acid derivatives as LPA receptor inhibitors

Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.

Isoxazolidine derivatives

Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. 

3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Compounds

Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.

Compounds of formula(I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive and inflammatory diseases.

Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.

Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same

1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.

1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Growing community of inventors

Parma, Italy

Andrea Rizzi